36 results
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
. MorphoSys is confident that the MANIFEST-2 data package – complemented by long-term Phase 2 results – will provide impactful evidence to regulatory
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
by a private health insurance in an amount of up to gross EUR 403.99 per month.
§ 17
Umzugspauschale
Sec. 17
Relocation Package
(1) Das Vorstandmitglied hat
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
by the full Supervisory Board. The Management Board’s total remuneration package and the pension contracts were thoroughly reviewed and then adjusted
SC14D9C
EX-99.1
MOR
Morphosys AG
15 Mar 24
Written communication relating to third party tender offer
4:46pm
and Europe by the middle of 2024. We are on track with this process and are confident that our comprehensive pelabresib data package will provide impactful … that many companies typically do following positive phase 3 data, and I can just reiterate that we remain confident that the comprehensive data package
SC14D9C
EX-99.2
MOR
Morphosys AG
14 Mar 24
Written communication relating to third party tender offer
4:52pm
Scientific Publications and Medical Education Intend to file for approval in U.S. and Europe in mid-2024 Submit comprehensive pelabresib data package
03
SC14D9C
EX-99.1
qb7g7hmenz
14 Mar 24
Written communication relating to third party tender offer
4:52pm
6-K
EX-99.2
aoc48h5k
14 Mar 24
Current report (foreign)
8:27am
SC14D9C
EX-99.4
v359lvt mfh6lgby64bm
13 Mar 24
Written communication relating to third party tender offer
5:22pm
6-K
EX-99.1
mqufd6seks3
13 Mar 24
Current report (foreign)
4:08pm
SC14D9C
EX-99.1
pxg454fyy0b 38g7e26
6 Feb 24
Written communication relating to third party tender offer
4:58pm
6-K
EX-99.2
ikwh hyx5wel
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
qf37juek6k
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
we7mx uvt
23 Mar 22
Current report (foreign)
4:15pm
6-K
EX-99.1
1usfdfr rc1rwy
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
SC TO-T
EX-99
i5prt163 a1f3h
16 Jun 21
Third party tender offer statement
4:52pm
6-K
EX-99.1
cx4dkwcn
12 May 21
MorphoSys and Incyte Announce First Patient Dosed in Phase 3
6:19am
6-K
EX-99.1
f8m21k m5b8bf
23 Mar 21
Current report (foreign)
3:53pm